Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research has been conducted over the last few decades to elucidate the role of TSGs in cancer development. In cancer, loss of TSG function occurs via the deletion or inactivation of two alleles, according to Knudson's two-hit model hypothesis. It has become clear that mutations in TSGs are recessive at the level of an individual cell; therefore, a single mutation in a TSG is not sufficient to cause carcinogenesis. However, many studies have identified candidate TSGs that do not conform with this standard definition, including genes inactivated by epigenetic silencing rather than by deletion. In addition, proteasomal degradation by ubiquitination, abnormal cellular localization, and transcriptional regulation are also involved in the inactivation of TSGs. This review incorporates these novel additional mechanisms of TSG inactivation into the existing two-hit model and proposes a revised multiple-hit model that will enable the identification of novel TSGs that can be used as prognostic and predictive biomarkers of cancer.
Introduction
Many genetic studies in different cancers have identified a small number of genes that must be mutated or altered to promote the growth of malignant cells [1] . The two main properties of cancer cells, uncontrolled cell growth and the ability to invade other tissues, are the result of these genetic and epigenetic alternations. Genetic alternations include genetic mutations, genomic instability, loss of heterozygosity (LOH), and gene copy number variation
The ubiquitin-proteasome degradation pathway Cellular levels of proteins encoded by TSGs and oncogenes must be critically regulated to prevent carcinogenesis and malignant progression. Levels of TSG products are often controlled by the ubiquitin-proteasome pathway, a specific cellular proteolysis mechanism. E3 ubiquitin ligases catalyze the polyubiquitination of their specific protein substrates by cooperation with the ubiquitin-activating enzyme E1 and the ubiquitin-conjugating enzyme E2, and then the modified substrates are degraded by the 26S proteasome [17] . Enhanced degradation of TSG products due to dysfunction of the ubiquitination-proteasome pathway or aberrant expression of E3 ligases may be associated with tumorigenesis. As an example, inactivation of TSG function via ubiquitin-proteasomal degradation is discussed below.
Inactivation of p53 TSG (TP53) by ubiquitin-proteasomal degradation
The p53 TSG (TP53) is inactivated in the majority of cancers [18, 19] . It negatively regulates the cell cycle and is involved in genomic stabilization and angiogenesis [18, 19] . Inactivation of TP53 by homozygous deletion (HD), LOH, point mutations, and/or methylation has been frequently reported in human cancers (Table 2 -9). In addition to these genetic inactivation mechanisms, the cellular p53 level is also regulated through ubiquitinationmediated degradation [20] . A number of RING finger domain-containing E3 ligases, including mouse double minute 2 homolog (MDM2), MDM4, herpesvirus-associated ubiquitin-specific protease (HAUSP), constitutively photomorphogenic 1 (COP1), Pirh2, and ARF-BP1, can ubiquitinate p53 [21] [22] [23] [24] [25] . However, MDM2 appears to be the dominant regulator, as the lethality of MDM2 deficiency can be rescued by the loss of TP53 [21, 26] . The E3 ligase activity of MDM2 towards p53 is significantly increased by heterodimerization with MDM4 [21, 26] . Gene amplification of MDM2 was observed in approximately 10% of tumors [21, 26] , most of which retained wild-type TP53. In some tumor cells, overexpression of MDM2 occur even in the absence of MDM2 gene amplification [27] . Additionally, overexpression of Table 2 . The expression and inactivation mechanisms of tumor suppressor genes in leukemia and brain cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case Table 4 . The expression and inactivation mechanisms of tumor suppressor genes in cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case Table 3 . The expression and inactivation mechanisms of tumor suppressor genes in head and neck and Lung cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case Table 5 . The expression and inactivation mechanisms of tumor suppressor genes in cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case Table 6 . The expression and inactivation mechanisms of tumor suppressor genes in cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case Table 7 . The expression and inactivation mechanisms of tumor suppressor genes in cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case Table 8 . The expression and inactivation mechanisms of tumor suppressor genes in Breast and Ovarian cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case Table 9 . The expression and inactivation mechanisms of tumor suppressor genes in cervical and endometrial cancer. Note: "-"no report found; "HD" homozygosity deletion; "NS" no significant difference; the average percent was calculated using total case divide by positive case
cancer cells, and impaired spatiotemporal dynamics of tumor suppressor protein signaling has been shown to be involved in carcinogenesis and malignant progression [41, 42] . Next, we discuss several examples of how the mislocalization of tumor suppressor proteins can lead to tumorigenesis.
Inactivation of RB1 by mislocalization RB1 is considered a classical TSG. The protein encoded by this gene is a negative regulator of the cell cycle. Inactivation of RB1 through somatic mutation, deletion, or epigenetic silencing in various cancers is summarized in Table 2 -9. Hypophosphorylated pRB binds to and represses the transcriptional activity of E2F family members, which control the expression of genes necessary for cell cycle progression [43] . By contrast, pRB that is serinephosphorylated by cyclin-dependent kinase 3 (CDK3)/cyclin-C has been shown to facilitate re-entry into the cell cycle by G0-arrested cells. pRB that is cytoplasmically mislocalized by exportin 1-mediated nuclear export may also promote tumor formation [44, 45] . In addition, some pRB-related proteins can also affect its subcellular localization. A-type nuclear lamins (lamin A/C), core components of the nuclear matrix, can tether pRB and lead to cell cycle arrest [46] . By contrast, co-expression of cyclin E and simian vacuolating virus 40 (SV40) large T antigen inactivates pRB by disrupting its nuclear accumulation [47] . Another report reveals that pRB export from nucleus is regulated by its association with exportin-1, which is dependent on CDK-mediated phosphorylation of pRB at C-terminal phosphoresidues [48] . These data imply that nucleocytoplasmic mislocalization of pRB could be effectively reversed by inhibition of CDK activity. Thus, CDK inhibitors have tremendous clinical potential and promise in human cancer.
Inactivation of TP53 by mislocalization
p53 is a transcription factor (TF) that activates stress response genes involved in cell cycle checkpoints or cell death in response to DNA damage [49, 50] . However, in several types of cancer (including colon cancer, breast cancer, ovarian cancer, retinoblastoma, and neuroblastoma), wild-type p53 is inactivated due to abnormal subcellular localization [51] . In these situations, the function and activity of p53 remains intact. p53 contains a nuclear import/ localization signal (NLS) and a nuclear export signal (NES) that mediate p53 translocation into the nucleus via nuclear transport receptors. For example, the function of p53 is also regulated by promyelocytic leukemia-nuclear bodies (PML-NBs) at the subnuclear level [52] . The PML protein forms a stable complex with p53 and cyclic AMP response element-binding protein (CREB) within PML-NBs and promotes p53 acetylation, which promotes apoptosis [53] . Loss of PML has been reported in many human cancers, so it is possible that functional inactivation of p53 could result from abnormal subcellular location induced by disruption of PML-NBs. In addition, several post-translational modifications of p53, such as sumoylation, glycosylation, neddylation, and ribosylation, also regulate p53 subcellular location [54] . p53 accumulation in the nucleus results in cell cycle arrest, senescence, and apoptosis. Thus, recent cancer treatment strategies attempted to induce wild type p53 nuclear retention or accumulation of p53 protein as a result of enhanced stabilization, resulting in apoptosis [55, 56] .
Inactivation of BRCA1 by mislocalization
The familial breast cancer susceptibility gene BRCA1 encodes a 220 kDa phosphorylatable TF with tumor suppressor activity. BRCA1 plays an important role in multiple biological pathways, including transcriptional regulation, proper genomic repair, cell proliferation, and apoptosis [57] . Reports of misregulation of BRCA1 through somatic mutation, deletion, or epigenetic silencing in various cancers are summarized in Table 2 -9. In addition, the subcellular localization of BRCA1 plays an important role in its tumor suppressor function. Many breast and ovarian cancer cell lines and primary tumors exhibit high levels of cytosolic BRCA1. The RING finger element of BRCA1 mediates nuclear import by association with its binding partner, BRCA1-associated RING domain protein 1 (BARD1) [58] . The structure of the BRCA1/BARD1 heterodimer predicts that the BRCA1 NES lies within the RING finger domain that mediates shuttling of BRCA1 into the cytoplasm [59] . This raised the possibility that BARD1 binding masks the NES at the N-terminus of BRCA1 and prevents association with chromosome region maintenance protein 1 (CRM1), thereby causing nuclear retention of BRCA1 [59] . Specifically, cancer-associated germline mutations in the C-terminus of BRCA1 restrict it to the cytosol and repress its nuclear function, particularly in response to DNA damage [57, 59, 60] . Furthermore, it is not known whether other RING finger domainbinding proteins such as BRCA1-associated protein 1 (BAP1) also interact with BRCA1 to inhibit its control of cell growth. In the context of cancer, studies into how the intracellular shuttling of BRCA1 and its misregulation by somatic mutations alter its activity could provide insights into novel clinical applications.
Inactivation of APC by mislocalization
Loss of APC from mutation, epigenetic silencing, or hypermethylation of the promoter has been reported in many human cancers (Table 2 -9). This tumor suppressor is generally localized within the cytoplasm of healthy cells but has been shown to localize to the nucleus of human cancer cells [61] , where it binds to and exports the oncogenic product β-catenin [62] . APC contains two classical NLSs and two functional NESs near the N-terminus that mediate shuttling between the nucleus and the cytoplasm by association with exportin-1 [63, 64] _ENREF_58. Direct regulation of APC during cell proliferation comes from casein kinase-2 (CK2), which binds to and phosphorylates APC at the N-terminus, resulting in its nuclear translocation [65] , [66] . In addition, the subcellular localization of APC is regulated by its binding partners. Other nuclear binding partners for APC are the protein tyrosine phosphatase PTP-BL, the TF activator protein-2α (AP-2α), and the nuclear export factor exportin-1 [66] . Recent research in mouse models revealed that nuclear APC regulates epithelial cell proliferation by inhibiting canonical WNT signaling in intestinal tissue, suggesting that the subcellular distribution of APC plays an important role in cancer progression [67] . Several therapeutic treatment approaches aimed at restoring APC localization and its function in Wnt/β-catenin signaling have been developed.
Inactivation of SMAD4 by mislocalization
Mothers against decapentaplegic homolog 4 (SMAD4) is a TSG associated with gastrointestinal carcinogenesis. As a member of the TGF-β signaling family, SMAD4 is involved in many cell functions including differentiation, apoptosis, and cell cycle control [68, 69] . In human cancers, the SMAD4 gene can be damaged by mutation or LOH or silenced by gene deletion (Table 2 -9). Furthermore, abnormal subcellular distribution of SMAD4 may also result in loss of its function. A previous study demonstrated that, in unstimulated cells, the NLS in its MAD homology 1 (MH1) domain and the leucine-rich NES in its linker region are both constitutively active, with the result that SMAD4 is shuttled continuously between the nucleus and the cytoplasm [70] . Activation of the SMAD4 NES is dependent on exportin-1, while the export of SMAD2/3 from the nucleus is clearly independent of this factor [71] . Treatment of cells with the exportin-1 inhibitor leptomycin B (LMB) causes a rapid accumulation of SMAD4 in the nucleus, which confirms that SMAD4 is exported by this specific exportin [71] . In addition, certain retention factors, including microtubules [72] and nuclear import proteins such as the E26 transformation-specific (ETS)-related TFs (ELFs) [73, 74] , have also been implicated in the regulation of the subcellular distribution of SMAD4. Previously, we found that, in advanced gastric carcinomas, 41% of samples that were negative for SMAD4 nuclear staining had moderate-to-high cytoplasmic SMAD4 staining. This pattern of SMAD4 accumulation correlated with cytoplasmic accumulation of SMAD2/3 [75] . Therefore, dysregulation of nuclecytoplasmic shuttling may be another mechanism leading to functional loss of nuclear SMAD4.
TF regulation
TFs are key drivers of cell proliferation, and maintain the balance of expression of proapoptotic and anti-apoptotic genes. These factors typically bind to specific enhancer elements and/or other proteins of the transcriptional machinery, and can also recruit co-activators or co-repressors and RNA polymerase II directly, leading to expression or repression of key regulatory genes involved in tumorigenesis. Here, we provide a basic overview of a few TSGs that are inactivated by aberrant TF regulation.
Inactivation of CDH1 by aberrant TF regulation E-cadherin (CDH1) is a cell adhesion molecule that is essential in maintaining the integrity of cell-cell contacts in epithelial cell layers [76] . Loss of CDH1 enhances the invasiveness of epithelial tumor cells [77] . Dysregulation of CDH1 occurs in many human cancers, as a result of CDH1 gene mutation, LOH, or epigenetic promoter methylation (Table 2 -9). Hypermethylation and chromatin remodeling of the CDH1 gene have emerged as the main mechanisms responsible for the downregulation of CDH1 in most carcinomas. It was recently reported that dysregulation of CDH1 expression also contributes to the progression of cancer. The Snail family TFs, including the zinc finger factors Snail and Slug, play a vital role in the transcriptional repression of CDH1 and induce epithelial-mesenchymal transition (EMT) by altering gene transcription during the invasion process [77] . The two-handed zinc finger proteins ZEB1 and ZEB2 and the basic helix-loop-helix (bHLH) family proteins E12/E47 are also able to repress CDH1 expression. TWIST1 is a transcriptional repressor of CDH1, and an inverse correlation between TWIST1 and CDH1 expression has been reported in invasive lobular breast carcinoma [77] . These findings implicated TWIST1 in tumor cell intravasation, the process through which tumor cells enter into the circulation to seed metastases. More recently, another study demonstrated that the tumor suppressor Kruppellike factor 6 (KLF6) directly transactivates the CDH1 promoter [78] . These combined findings highlight multiple mechanisms through which aberrant TF regulation can lead to inactivation of the CDH1 gene.
Inactivation of PTEN by aberrant TF regulation
Phosphatase and tensin homolog on chromosome 10 (PTEN) is a potent TSG located at chromosome 10q23.31. In many human cancers, PTEN is inactivated by mutation or epigenetic mechanisms, and PTEN protein stability or function can be weakened by other mechanisms [79, 80] . Inactivation of PTEN by HD, LOH, point mutations, or aberrant methylation is summarized in Table 2 -9. However, in many cancers, the PTEN gene is intact, but appears to be transcriptionally silent. PTEN is a rapidly degraded protein with a half-life of less than 4 hours, and it appears that many of the genetic alterations found in PTEN in cancer cells further accelerate this rapid degradation. Sukhatme et al. found that the early growth response 1 (EGR1) TF binds directly to a consensus motif in the PTEN promoter and activates gene transcription, and is necessary for the upregulation of PTEN mRNA in response to UV light and other stress stimuli [81, 82] . In addition, Stambolic et al. demonstrated that PTEN transcription can also be induced by p53, which binds to a site in the promoter close to the EGR1-binding site [83] . The TP53 TSG is the most common functionally lost gene in human cancers. Moreover, several reports show that the APE1/Ref-1 pathway also regulates the expression of PTEN [84, 85] . Therefore, it is possible that dysregulation of these TFs can inactivate PTEN function.
Inactivation of KiSS1 by aberrant TF regulation
KiSS1 was first identified as a TSG in melanoma. Lee et al. found that the expression of KiSS1 was negatively related to the metastasis potential of melanoma cell lines and clinical samples [86] . Later, the loss or downregulation of KiSS1 was found in various metastatic cancers, including ovarian cancer, endometrial cancer, gastric cancer, bladder cancer, brain cancer, and prostate cancer, which further verify its metastatic suppressor role in cancer [87] . Besides the above genetic and epigenetic r e g u l a t i o n , d y s r e g u l a t i o n of TF was also demonstrated to contribute the d o w n r e g u l a t i o n of KiSS1. Previous study showed that transcription factors, including TCF21, CUX1, YY1, EAP1, and TTF1, could regulate the expression of KiSS1 at mRNA level [88, 89] . Recent research showed that loss of TCF21 in metastatic melanoma would result in the downregulation of KiSS1 and subsequently contribute to metastasis [88] . Furthermore, inactivation of CUX1 was also reported in acute myeloid leukemia [90] . Therefore, the above-mentioned data suggesting aberrant regulation of TFs would become an extra hit to inactivate KiSS1 gene. Hence, a better understanding of the multiple mechanisms that regulate TSG expression and their roles in cancer progression will enhance current treatment strategies.
Conclusion
Many reports demonstrate that the "two-hit" model, in which a genetic and an epigenetic event lead to loss of TSG expression, does not fully explain the inactivation of TSGs in human cancers. Therefore, we propose a revised "multiple-hit" model for the inactivation of TSGs, which includes a non-genetic/epigenetic event such as transcriptional regulation, proteasome degradation, or abnormal nucleocytoplasmic shuttling (Fig. 1) . This revised "multiple-hit" model incorporates the inactivation of TSGs at the molecular level and could suggest novel targets for anti-cancer therapy. 
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